Quo vadis, biotech? (Part 1)

The recent increase in the capitalization value of the biotechnology indust ry appears to be sustainable. The phenomenon is interpreted as an acknowled gement by the markets that this industry has become the main source of inno vation for the pharmaceutical industry. In addition, biotechnology is begin ning to impact on other industries. However, from a methodological and stra tegic point of view, the biotechnology industry is still too fragmented. Co nsolidation along the lines of value generation in drug research and develo pment, however, will occur. Over the next 5 to 10 years, the biotechnology industry will remain the fastest growing industry in the health care arena.